Skip to main content
. 2018 Apr 19;17(6):8244–8252. doi: 10.3892/mmr.2018.8894

Figure 1.

Figure 1.

Expression of miR-122 and TRIM29 in patients with NPC and cell lines. Quantitative analysis of (A) miR-122 and (B) TRIM29 in NPC samples with or without metastasis, respectively, was performed. p-NPC, NPC samples without metastasis; m-NPC, NPC samples with metastasis. Data are presented as the mean ± standard deviation, n=3. *P<0.05 and **P<0.01 vs. normal; #P<0.05 vs. p-NPC. (C) The overall survival rate of patients with NPC in miR-122 high and low expression level groups. (D) The overall survival rate of NPC patients in TRIM29 high and low expression level groups. Quantitative analyses of (E) miR-122 and (F) TRIM29 in NPC cell lines were performed following radiation treatment. (G) Western blot analysis and (H) determination of the expression of TRIM29 in NPC cell lines following radiation treatment. Data are presented as mean ± standard deviation, n=4. *P<0.05 and **P<0.01 vs. groups without radiation treatment. NPC, nasopharyngeal carcinoma; TRIM29, tripartite motif-containing protein 29; miR, microRNA.